Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency
Information source: Eli Lilly and Company
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Growth Hormone Deficiency
Intervention: Somatropin (Drug); Somatropin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Eli Lilly and Company Official(s) and/or principal investigator(s): Call 1-877-CTLILLY (1-877-285-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study Chair, Affiliation: Eli Lilly and Company
Summary
Multi-center, randomized, controlled, open-label, phase III study comparing the effects of
two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months
of treatment, on height velocity in early pubertal children with growth hormone deficiency
(GHD). The study will be conducted in Italy. Approximately 26 subjects will participate in
this study, distributed as 13 in the in-label dosage group (group A) and 13 in the doubled
dosage group (group B).
Clinical Details
Official title: Efficacy and Safety of a High Dosage Compared to the Label Dosage of Humatrope in Early Pubertal Stage Children With Growth Hormone Deficiency
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint
Secondary outcome: Change From Baseline to 12-Month and 24-Month Endpoints in Height Standard Deviation Score (SDS)Height Velocity Standard Deviation Score (SDS) at 24 Month Endpoint
Eligibility
Minimum age: N/A.
Maximum age: 14 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Height velocity (cm/y) less than 25th percentile at the time of diagnosis.
- diagnosis of GHD
- Replacement therapy at label dosage (from 0. 025 to 0. 035 mg/kg/day) must be started
at least 1 year before the enrolment in this study, but at most 3 years before
enrolment
- Bone age less than 12 years for girls and less than 14 years for boys. This
assessment should be made by the central reader of bone ages, based on the x-ray
taken at Visit 0.
- Informed consent obtained from either both of the subject's parents or legal
representative.
Exclusion Criteria:
- Pubertal clinical stage less than 2 and greater than 3 according to Tanner score (for
male subjects a volume of testicle greater than 15 mL).
- Any evidence of active malignancy. In case of previous surgical removal of both
diencephalic and hypophysial masses, an MRI, performed within six months before
enrollment into the study, must exclude the growth of residual tumoral tissue.
- Any known chronic disease such as diabetes mellitus, hepatic disease (defined by
elevated liver enzymes 3-fold the upper limit of normal ranges), renal disease with
creatinine levels greater than 130 micromol/L, or congestive heart failure.
- Glucocorticoid therapy in supra physiological doses (inhaled corticoids will be
accepted if below 3 puffs/day, for no more than 10 days consecutively).
- Current or previous therapy with any therapy that may directly influence growth,
including growth hormone releasing hormone, estrogens and anabolic steroids.
Locations and Contacts
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bari, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bologna, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Catania, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Milano, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Novara, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Parma, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pavia, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pisa, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Torino, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Verona, Italy
Additional Information
Lilly Clinical Trial Registry
Starting date: March 2004
Last updated: June 8, 2009
|